Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1 results about "Dexrazoxane" patented technology

Dexrazoxane is used to reduce the risk and severity of heart damage caused by doxorubicin treatment and similar cancer chemotherapy medications.

Application of MSR1 inhibitor in preparation of anti-tumor immunopotentiator

The invention discloses an application of an MSR1 inhibitor in preparation of an anti-tumor immunopotentiator. The MSR1 inhibitor is composed of doxylamine, trafenotide, dexrazoxane and clavulanic acid. The invention discloses application of an MSR1 inhibitor combined with an immune checkpoint inhibitor in preparation of a medicine for treating solid tumors. The MSR1 inhibitor disclosed by the invention is used as an anti-tumor immunopotentiator and is combined with an immune checkpoint inhibitor to treat solid tumors, so that the curative effect of tumor immunotherapy can be improved. The MSR1 inhibitor can induce tumor-related macrophages to be differentiated into anti-tumor subtypes, anti-tumor immunity is driven through phagocytosis and generation of cell factors, and a new method is provided for improving the curative effect of tumor immunotherapy.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)